StreetInsider.com News Articles

RBC Capital Downgrades Biohaven Pharma (BHVN) to Sector Perform

Tue, 08 Sep 2026 02:19:22 -0400

RBC Capital analyst Leonid Timashev downgraded Biohaven Pharma (NYSE: BHVN) from Outperform to Sector Perform with a price target of $19.00 (from $23.00).

The analyst comments: “We had been looking for the Kv7 program to provide an upside catalyst and bridge the gap to additional data from the degraders, helping balance the overall risk profile. With shares up ~100% since the lows earlier this year, we think this has largely occurred, as the Kv7 deal has strengthened the balance sheet enabling BHVN to have line of sight to future readouts. From here, we still see longer term upside, but balanced by

RBC Capital Downgrades Biohaven Pharma (BHVN) to Sector Perform

Tue, 08 Sep 2026 02:19:22 -0400

RBC Capital analyst Leonid Timashev downgraded Biohaven Pharma (NYSE: BHVN) from Outperform to Sector Perform with a price target of $19.00 (from $23.00).

Canaccord Reiterates Buy Rating on Biohaven Pharma (BHVN)

Fri, 28 Aug 2026 08:10:26 -0400

Canaccord analyst Sumant Kulkarni reiterated a Buy rating and $21.00 price target on Biohaven Pharma (NYSE: BHVN).

The analyst commented: "Yesterday (8/26), BHVN announced that it is outlicensing opakalim for focal epilepsy to SK Biopharmaceuticals. BHVN will receive $400mn in cash ($350mn upfront, $50mn a year after closing), $150mn in development/regulatory milestones and future royalties, and $245mn to buy out BHVN's obligations to Knopp Biosciences (from which BHVN acquired opakalim). Recall that opakalim (a Kv7 activator) has a somewhat de-risked mechanism (competitor Xenon's product has solid data) and could be best-in-class based on its safety/tolerability. Importantly, we are waiting for Phase

H.C. Wainwright Reiterates Neutral Rating on Biohaven Pharma (BHVN)

Thu, 27 Aug 2026 07:07:33 -0400

H.C. Wainwright analyst Douglas Tsao reiterated a Neutral rating and $10.00 price target on Biohaven Pharma (NYSE: BHVN).

The analyst commented: "Today, Biohaven announced a global licensing and collaboration agreement granting SK Biopharmaceuticals (326030.KS; Not rated) an exclusive worldwide license to its Kv7 ion channel platform, led by opakalim (BHV-7000), in Phase 2/3 development for focal epilepsy. Biohaven receives $400M in cash consideration, $350M at closing and $50M one year later, is eligible for up to $150M in development and regulatory milestones, and will receive tiered royalties in the mid-teens to low twenties on US net sales of opakalim and mid-single-digit

TD Cowen Reiterates Buy Rating on Biohaven Pharma (BHVN)

Wed, 26 Aug 2026 11:01:56 -0400

TD Cowen analyst Tyler Van Buren reiterated a Buy rating and $30.00 price target on Biohaven Pharma (NYSE: BHVN)

The analyst comments "The SK/Opakalim deal terms are attractive as Biohaven will likely capture more profit than if it launched the drug itself. Additionally, the $400MM upfront, improved milestone situation, and SK assuming development costs extends the cash runway closer to 2 years. We believe this significantly reduces the downside risk to near-term RISE3 data and should free up investment into the broader pipeline."

For an analyst ratings summary and ratings history on Biohaven Pharma click here. For more ratings news on

Biohaven Pharma (BHVN) PT Lowered to $30 at Raymond James

Wed, 26 Aug 2026 10:17:53 -0400

Raymond James analyst Chris Raymond lowered the price target on Biohaven Pharma (NYSE: BHVN) to $30.00 (from $50.00) while maintaining a Strong Buy rating.

The analyst comments "Remain Strong Buy rated on BHVN shares but lowering PT to $30 from $50 as we remove full economic benefit from opakalim from the model. While this asset was a cornerstone of this name’s valuation, so, too – recently – was a meaningful looming balance sheet shortfall (we had anticipated cash only through the next ~12 months). While monetizing this asset so close to P2/3 data was not on our bingo card, by our

Biohaven Pharma (BHVN) PT Lowered to $30 at Raymond James

Wed, 26 Aug 2026 10:17:53 -0400

Raymond James analyst Chris Raymond lowered the price target on Biohaven Pharma (NYSE: BHVN) to $30.00 (from $50.00) while maintaining a Strong Buy rating.

Biohaven licenses Kv7 epilepsy platform to SK Biopharma for up to $795M

Wed, 26 Aug 2026 07:05:33 -0400

Biohaven Ltd. (NYSE: BHVN) and SK Biopharmaceuticals Co., Ltd. announced a global licensing and collaboration agreement under which SK Biopharmaceuticals will receive an exclusive worldwide license to Biohaven's Kv7 ion channel platform, including its lead candidate opakalim (BHV-7000), a Kv7.2/7.3 potassium channel activator in Phase 2/3 development for focal epilepsy.

Under the terms of the agreement, SK Biopharmaceuticals will make upfront and milestone payments to Biohaven totaling up to $795 million. Biohaven will receive $400 million in near-term cash, comprising $350 million at closing and $50 million payable in 2027. An additional $150 million is available through development and regulatory milestones.

Form 8-K Biohaven Ltd. For: Aug 26

Wed, 26 Aug 2026 06:39:00 -0400

si-local-file:///var/storage/secattach/20260826/26976987.html

Form 8-K Biohaven Ltd. For: Aug 26

Wed, 26 Aug 2026 06:39:00 -0400

si-local-file:///var/storage/secattach/20260826/26976987.html

Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy

Wed, 26 Aug 2026 02:36:00 -0400

SK Biopharmaceuticals to provide upfront and milestone payments related to the Kv7 platform up to $795 million, along with tiered royalties to Biohaven ranging from the mid-teens to low twenties on U.S. net sales of opakalim.
Opakalim, the lead candidate from Biohaven's Kv7 platform, is a next-generation, selective Kv7.2/7.3 potassium channel activator currently in Phase 2/3 development for focal epilepsy, with topline results from the RISE3 trial expected in 2H 2026. It is designed to offer an easy-to-use, once-daily oral treatment without the need for titration and a

Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy

Wed, 26 Aug 2026 02:36:00 -0400

SK Biopharmaceuticals to provide upfront and milestone payments related to the Kv7 platform up to $795 million, along with tiered royalties to Biohaven ranging from the mid-teens to low twenties on U.S. net sales of opakalim.

Opakalim, the lead candidate from Biohaven's Kv7 platform, is a next-generation, selective Kv7.2/7.3 potassium channel activator currently in Phase 2/3 development for focal epilepsy, with topline results from the RISE3 trial expected in 2H 2026. It is designed to offer an easy-to-use, once-daily oral treatment without the need for titration and a

Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy

Wed, 26 Aug 2026 02:36:00 -0400

SK Biopharmaceuticals to provide upfront and milestone payments related to the Kv7 platform up to $795 million, along with tiered royalties to Biohaven ranging from the mid-teens to low twenties on U.S. net sales of opakalim.

Opakalim, the lead candidate from Biohaven's Kv7 platform, is a next-generation, selective Kv7.2/7.3 potassium channel activator currently in Phase 2/3 development for focal epilepsy, with topline results from the RISE3 trial expected in 2H 2026. It is designed to offer an easy-to-use, once-daily oral treatment without the need for titration and a

Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy

Wed, 26 Aug 2026 02:36:00 -0400

SK Biopharmaceuticals to provide upfront and milestone payments related to the Kv7 platform up to $795 million, along with tiered royalties to Biohaven ranging from the mid-teens to low twenties on U.S. net sales of opakalim.

Opakalim, the lead candidate from Biohaven's Kv7 platform, is a next-generation, selective Kv7.2/7.3 potassium channel activator currently in Phase 2/3 development for focal epilepsy, with topline results from the RISE3 trial expected in 2H 2026. It is designed to offer an easy-to-use, once-daily oral treatment without the need for titration and a

Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy

Wed, 26 Aug 2026 02:36:00 -0400

SK Biopharmaceuticals to provide upfront and milestone payments related to the Kv7 platform up to $795 million, along with tiered royalties to Biohaven ranging from the mid-teens to low twenties on U.S. net sales of opakalim.

Opakalim, the lead candidate from Biohaven's Kv7 platform, is a next-generation, selective Kv7.2/7.3 potassium channel activator currently in Phase 2/3 development for focal epilepsy, with topline results from the RISE3 trial expected in 2H 2026. It is designed to offer an easy-to-use, once-daily oral treatment without the need for titration and a

Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy

Wed, 26 Aug 2026 02:36:00 -0400

SK Biopharmaceuticals to provide upfront and milestone payments related to the Kv7 platform up to $795 million, along with tiered royalties to Biohaven ranging from the mid-teens to low twenties on U.S. net sales of opakalim.

Opakalim, the lead candidate from Biohaven's Kv7 platform, is a next-generation, selective Kv7.2/7.3 potassium channel activator currently in Phase 2/3 development for focal epilepsy, with topline results from the RISE3 trial expected in 2H 2026. It is designed to offer an easy-to-use, once-daily oral treatment without the need for titration and a

Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy

Wed, 26 Aug 2026 02:36:00 -0400

SK Biopharmaceuticals to provide upfront and milestone payments related to the Kv7 platform up to $795 million, along with tiered royalties to Biohaven ranging from the mid-teens to low twenties on U.S. net sales of opakalim.

Opakalim, the lead candidate from Biohaven's Kv7 platform, is a next-generation, selective Kv7.2/7.3 potassium channel activator currently in Phase 2/3 development for focal epilepsy, with topline results from the RISE3 trial expected in 2H 2026. It is designed to offer an easy-to-use, once-daily oral treatment without the need for titration and a

Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy

Wed, 26 Aug 2026 02:36:00 -0400

SK Biopharmaceuticals to provide upfront and milestone payments related to the Kv7 platform up to $795 million, along with tiered royalties to Biohaven ranging from the mid-teens to low twenties on U.S. net sales of opakalim.

Opakalim, the lead candidate from Biohaven's Kv7 platform, is a next-generation, selective Kv7.2/7.3 potassium channel activator currently in Phase 2/3 development for focal epilepsy, with topline results from the RISE3 trial expected in 2H 2026. It is designed to offer an easy-to-use, once-daily oral treatment without the need for titration and a

Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy

Wed, 26 Aug 2026 02:36:00 -0400

SK Biopharmaceuticals to provide upfront and milestone payments related to the Kv7 platform up to $795 million, along with tiered royalties to Biohaven ranging from the mid-teens to low twenties on U.S. net sales of opakalim.

Opakalim, the lead candidate from Biohaven's Kv7 platform, is a next-generation, selective Kv7.2/7.3 potassium channel activator currently in Phase 2/3 development for focal epilepsy, with topline results from the RISE3 trial expected in 2H 2026. It is designed to offer an easy-to-use, once-daily oral treatment without the need for titration and a

Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy

Wed, 26 Aug 2026 02:36:00 -0400

SK Biopharmaceuticals to provide upfront and milestone payments related to the Kv7 platform up to $795 million, along with tiered royalties to Biohaven ranging from the mid-teens to low twenties on U.S. net sales of opakalim.

Opakalim, the lead candidate from Biohaven's Kv7 platform, is a next-generation, selective Kv7.2/7.3 potassium channel activator currently in Phase 2/3 development for focal epilepsy, with topline results from the RISE3 trial expected in 2H 2026. It is designed to offer an easy-to-use, once-daily oral treatment without the need for titration and a

Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy

Wed, 26 Aug 2026 02:36:00 -0400

SK Biopharmaceuticals to provide upfront and milestone payments related to the Kv7 platform up to $795 million, along with tiered royalties to Biohaven ranging from the mid-teens to low twenties on U.S. net sales of opakalim.

Opakalim, the lead candidate from Biohaven's Kv7 platform, is a next-generation, selective Kv7.2/7.3 potassium channel activator currently in Phase 2/3 development for focal epilepsy, with topline results from the RISE3 trial expected in 2H 2026. It is designed to offer an easy-to-use, once-daily oral treatment without the need for titration and a

Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy

Wed, 26 Aug 2026 02:36:00 -0400

SK Biopharmaceuticals to provide upfront and milestone payments related to the Kv7 platform up to $795 million, along with tiered royalties to Biohaven ranging from the mid-teens to low twenties on U.S. net sales of opakalim.

Opakalim, the lead candidate from Biohaven's Kv7 platform, is a next-generation, selective Kv7.2/7.3 potassium channel activator currently in Phase 2/3 development for focal epilepsy, with topline results from the RISE3 trial expected in 2H 2026. It is designed to offer an easy-to-use, once-daily oral treatment without the need for titration and a

Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy

Wed, 26 Aug 2026 02:36:00 -0400

SK Biopharmaceuticals to provide upfront and milestone payments related to the Kv7 platform up to $795 million, along with tiered royalties to Biohaven ranging from the mid-teens to low twenties on U.S. net sales of opakalim.

Opakalim, the lead candidate from Biohaven's Kv7 platform, is a next-generation, selective Kv7.2/7.3 potassium channel activator currently in Phase 2/3 development for focal epilepsy, with topline results from the RISE3 trial expected in 2H 2026. It is designed to offer an easy-to-use, once-daily oral treatment without the need for titration and a

Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy

Wed, 26 Aug 2026 02:36:00 -0400

SK Biopharmaceuticals to provide upfront and milestone payments related to the Kv7 platform up to $795 million, along with tiered royalties to Biohaven ranging from the mid-teens to low twenties on U.S. net sales of opakalim.

Opakalim, the lead candidate from Biohaven's Kv7 platform, is a next-generation, selective Kv7.2/7.3 potassium channel activator currently in Phase 2/3 development for focal epilepsy, with topline results from the RISE3 trial expected in 2H 2026. It is designed to offer an easy-to-use, once-daily oral treatment without the need for titration and a

Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy

Wed, 26 Aug 2026 02:36:00 -0400

SK Biopharmaceuticals to provide upfront and milestone payments related to the Kv7 platform up to $795 million, along with tiered royalties to Biohaven ranging from the mid-teens to low twenties on U.S. net sales of opakalim.

Opakalim, the lead candidate from Biohaven's Kv7 platform, is a next-generation, selective Kv7.2/7.3 potassium channel activator currently in Phase 2/3 development for focal epilepsy, with topline results from the RISE3 trial expected in 2H 2026. It is designed to offer an easy-to-use, once-daily oral treatment without the need for titration and a